Summarized by Masters of Longevity from MedTech Dive.
Medicare expansion talk is boosting Dexcom while Abbott faces pricing headwinds.
Key Takeaways
- Medicare expansion is expected to broaden CGM coverage.
- Dexcom has not seen pricing degradation and is taking share.
- Abbott has faced pricing pressure and slower Type 2 growth.
